Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Amortizatization of Intangibles (2019 - 2023)

Historic Amortizatization of Intangibles for Marker Therapeutics (MRKR) over the last 5 years, with Q1 2023 value amounting to $153518.0.

  • Marker Therapeutics' Amortizatization of Intangibles fell 4047.13% to $153518.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $786972.0, marking a year-over-year decrease of 2283.97%. This contributed to the annual value of $891343.0 for FY2022, which is 1206.64% down from last year.
  • Per Marker Therapeutics' latest filing, its Amortizatization of Intangibles stood at $153518.0 for Q1 2023, which was down 4047.13% from $151897.0 recorded in Q4 2022.
  • Marker Therapeutics' 5-year Amortizatization of Intangibles high stood at $259170.0 for Q2 2022, and its period low was $44211.0 during Q1 2019.
  • Over the past 5 years, Marker Therapeutics' median Amortizatization of Intangibles value was $222387.0 (recorded in 2022), while the average stood at $166471.4.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first surged by 44256.34% in 2020, then crashed by 4059.49% in 2022.
  • Quarter analysis of 5 years shows Marker Therapeutics' Amortizatization of Intangibles stood at $46540.0 in 2019, then skyrocketed by 442.56% to $252509.0 in 2020, then increased by 1.26% to $255697.0 in 2021, then tumbled by 40.59% to $151897.0 in 2022, then increased by 1.07% to $153518.0 in 2023.
  • Its last three reported values are $153518.0 in Q1 2023, $151897.0 for Q4 2022, and $222387.0 during Q3 2022.